MedTrace Logo

Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis

NCT04560790 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2022-08-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of BD111 CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy administered via corneal injection in participants with refractory herpetic viral keratitis.

Conditions

  • Viral Keratitis
  • Blindness Eye
  • Herpes Simplex Virus Infection
  • Cornea

Interventions

DRUG

BD111 Adult single group Dose

3-6 Participants will receive a single group dose administered via corneal injection in the study eye.

Sponsors & Collaborators

  • Eye & ENT Hospital of Fudan University

    collaborator OTHER

  • Shanghai BDgene Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yujia Cai, PhD · Shanghai BDgene Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-04
Primary Completion
2022-07-05
Completion
2022-07-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04560790 on ClinicalTrials.gov